ESR1 and breast carcinoma: By employing oestrogen receptor alpha as a positive marker we developed an immunocytochemical assay which we applied to a small number of ER+ metastatic breast cancer samples, however this technique identified minimal numbers of CTCs despite evidence of their presence on CellSearch.